FDA clearance of the IND will enable Vivoryon to initiate its U.S.
- FDA clearance of the IND will enable Vivoryon to initiate its U.S.
- Phase 2 clinical trial program for varoglutamstat (PQ912) in Alzheimer's disease as planned.
- The trial design includes a drug-titration phase and a composite Neuropsychological Test Battery (NTB) score for assessing cognitive efficacy.
- Data on electroencephalography (EEG) and cerebrospinal fluid (CSF) biomarkers will be complementary to the already active Phase 2b EU trial, VIVIAD.